Today: 7 February 2026
Subscribe
Browse Category

NASDAQ:TRIP News 14 November 2025 - 23 January 2026

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings (BKNG) stock slips as Booking.com expands Navan tie-up ahead of Feb. 18 results

Booking Holdings shares slipped 0.25% to $5,150.90 Thursday, bucking gains in broader U.S. indexes and sector peers like Expedia. Trading volume reached about 220,000 shares. The company set February 18 for its fourth-quarter and full-year results release. Navan announced an expanded API integration with Booking.com to offer more lodging options for business travelers.
23 January 2026
······
Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor (TRIP) Stock Edges Higher as Mizuho Upgrade Backs Cost Cuts, Viator Merger and AI Pivot – November 14, 2025

Tripadvisor, Inc. (NASDAQ: TRIP) returned to investors’ good graces on Friday after Mizuho upgraded the online travel company and lifted its price target, signaling Wall Street is starting to warm to an aggressive restructuring that includes layoffs, a Viator merger and a deeper bet on AI-powered travel experiences. Investing.com+1 As of mid‑day Friday, Tripadvisor shares were trading around $15.00, up roughly 1.5% from Thursday’s close at $14.78, though still well below their 52‑week high of $20.16. Investing.com+1 The bounce follows a bruising 6.75% slide on Thursday, when the stock sold off with the broader market despite recently reporting better‑than‑expected Q3
14 November 2025
···

Stock Market Today

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop